Instrumentl eFile Render
Object ID: 202222979349301767 - Rendered 2024-05-07
TIN: 52-1986675
Form
990
Department of the Treasury
Internal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to
www.irs.gov/Form990
for instructions and the latest information.
OMB No. 1545-0047
20
21
Open to Public Inspection
A
For the 2021 calendar year, or tax year beginning
01-01-2021
, and ending
12-31-2021
B
Check if applicable:
Address change
Name change
Initial return
Final return/terminated
Amended return
Application pending
C
Name of organization
FOUNDATION FOR THE NATIONAL INSTITUTES
OF HEALTH INC
Doing business as
Number and street (or P.O. box if mail is not delivered to street address)
11400 ROCKVILLE PIKE 600
Room/suite
City or town, state or province, country, and ZIP or foreign postal code
NORTH BETHESDA
,
MD
20852
D Employer identification number
52-1986675
E Telephone number
G
Gross receipts $
119,637,840
F
Name and address of principal officer:
DONALD M HILL
11400 ROCKVILLE PIKE 600
NORTH BETHESDA
,
MD
20852
I
Tax-exempt status:
501(c)(3)
501(c)
(
)
(insert no.)
4947(a)(1)
or
527
J
Website:
HTTP://WWW.FNIH.ORG
H(a)
Is this a group return for
subordinates?
Yes
No
H(b)
Are all subordinates
included?
Yes
No
If "No," attach a list. See instructions.
H(c)
Group exemption number
K
Form of organization:
Corporation
Trust
Association
Other
L
Year of formation:
1996
M
State of legal domicile:
MD
Part I
Summary
1
Briefly describe the organization’s mission or most significant activities:
THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND MANAGES ALLIANCES WITH PUBLIC ANDPRIVATE INSTITUTIONS IN SUPPORT OF THE MISSION OF THE NIH, THE WORLD'S PREMIER MEDICAL RESEARCH AGENCY. THE FOUNDATION, ALSO KNOWN AS THE FNIH, WORKS WITH ITS PARTNERS TO ACCELERATE BIOMEDICAL RESEARCH AND STRATEGIES AGAINST DISEASES AND HEALTH CONCERNS IN THE UNITED STATES AND ACROSS THE GLOBE. THE FNIH ORGANIZES AND ADMINISTERS RESEARCH PROJECTS; SUPPORTS EDUCATION AND TRAINING OF NEW RESEARCHERS; ORGANIZES EDUCATIONAL EVENTS AND SYMPOSIA; AND ADMINISTERS A SERIES OF FUNDS SUPPORTING A WIDE RANGE OF HEALTH ISSUES. ESTABLISHED BY CONGRESS IN 1990, THE FNIH IS A NOT-FOR-PROFIT 501(C)(3) CHARITABLE ORGANIZATION.
2
Check this box
3
Number of voting members of the governing body (
Part VI
, line 1a)
........
3
24
4
Number of independent voting members of the governing body (
Part VI
, line 1b)
.....
4
24
5
Total number of individuals employed in calendar year 2021 (
Part V
, line 2a)
......
5
86
6
Total number of volunteers (estimate if necessary)
.............
6
24
7a
Total unrelated business revenue from
Part VIII
, column (C), line 12
........
7a
0
b
Net unrelated business taxable income from Form 990-T, Part I, line 11
.........
7b
0
Prior Year
Current Year
8
Contributions and grants (
Part VIII
, line 1h)
.........
98,343,956
105,993,785
9
Program service revenue (
Part VIII
, line 2g)
.........
0
50,000
10
Investment income (
Part VIII
, column (A), lines 3, 4, and 7d )
....
1,793,315
1,523,894
11
Other revenue (
Part VIII
, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)
42,551
38,012
12
Total revenue—add lines 8 through 11 (must equal
Part VIII
, column (A), line 12)
100,179,822
107,605,691
13
Grants and similar amounts paid (
Part IX
, column (A), lines 1–3 )
...
23,094,805
20,925,571
14
Benefits paid to or for members (
Part IX
, column (A), line 4)
.....
0
0
15
Salaries, other compensation, employee benefits (
Part IX
, column (A), lines 5–10)
11,036,676
11,200,771
16a
Professional fundraising fees (
Part IX
, column (A), line 11e)
.....
0
0
b
Total fundraising expenses (
Part IX
, column (D), line 25)
112,270
17
Other expenses (
Part IX
, column (A), lines 11a–11d, 11f–24e)
....
24,522,875
26,276,294
18
Total expenses. Add lines 13–17 (must equal
Part IX
, column (A), line 25)
58,654,356
58,402,636
19
Revenue less expenses. Subtract line 18 from line 12
.......
41,525,466
49,203,055
Beginning of Current Year
End of Year
20
Total assets (
Part X
, line 16)
.............
171,939,741
221,939,759
21
Total liabilities (
Part X
, line 26)
.............
10,735,525
10,990,437
22
Net assets or fund balances. Subtract line 21 from line 20
.....
161,204,216
210,949,322
Part II
Signature Block
Sign Here
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
Signature of officer
Date
Type or print name and title
Paid Preparer Use Only
Print/Type preparer's name
Preparer's signature
Date
Check
if
self-employed
PTIN
Firm's name
Firm's EIN
Firm's address
Phone no.
May the IRS discuss this return with the preparer shown above? (see instructions)
..........
Yes
No
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y
Form
990
(2021)
Form 990 (2021)
Page
2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response or note to any line in this
Part III
..............
1
Briefly describe the organization’s mission:
SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES.
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ?
.....................
Yes
No
If "Yes," describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program
services?
...........................
Yes
No
If "Yes," describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a
(Code:
) (Expenses $
50,592,188
including grants of $
19,914,025
) (Revenue $
50,000
)
SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMSPROGRAM ONE - RESEARCH PROGRAMS -ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)COMBATING THE PANDEMIC WHEN DESPERATELY ILL COVID-19 PATIENTS FIRST BEGAN KNOCKING AT THE DOORS OF U.S. HOSPITALS, HEALTHCARE WORKERS FRANTICALLY SOUGHT TO DEVELOP EFFECTIVE TREATMENTS FOR THE DISEASE. ACROSS THE WORLD, INDIVIDUAL SCIENTISTS AS WELL AS RESEARCH INSTITUTIONS LAUNCHED HUNDREDS OF STUDIES TO TEST VARIOUS POTENTIAL REMEDIES. UNFORTUNATELY, MANY OF THESE STUDIES WERE TOO SMALL OR INADEQUATELY DESIGNED TO YIELD CONCLUSIVE RESULTS. MEANWHILE, A NUMBER OF UNSUBSTANTIATED REPORTS OF "EFFECTIVE" TREATMENTS FLOODED THE MEDIA, WHICH DID LITTLE TO RELIEVE THE "INFODEMIC" OVERWHELMING THE HEALTHCARE WORKERS TRYING TO HELP THESE PATIENTS.A NATIONALLY COORDINATED, FOCUSED PLAN FOR ADDRESSING THE PANDEMIC WAS CLEARLY NEEDED AND DR. FRANCIS COLLINS CALLED ON THE FNIH TO CREATE A SOLUTION. THE RESULTING ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) PARTNERSHIP WAS FORMED IN RECORD TIME IN APRIL 2020. OVER THE FOLLOWING 10 MONTHS, ACTIV REVIEWED MORE THAN 800 POTENTIAL COVID-19 TREATMENTS AND LAUNCHED 11 ROBUSTLY DESIGNED "MASTER PROTOCOL" CLINICAL TRIALS, EACH CAPABLE OF TESTING MULTIPLE DRUGS IN A RELEVANT PATIENT POPULATION AND FUNDED THROUGH NIH BY THE U.S. GOVERNMENT'S OPERATION WARP SPEED INITIATIVE. SINCE ITS INCEPTION IN APRIL 2020, THE ACTIV TRIAL NETWORKS HAVE TESTED OVER 30 THERAPIES FOR EFFECTIVENESS AGAINST COVID-19.OF THESE PROMISING LEADS, SEVERAL HAVE ALREADY REPORTED RESULTS, WITH A MAJORITY OF THE TRIALS DUE TO READ OUT BY THE FALL OF 2022. DURING 2021, DATA FROM THE ACTIV TRIALS CONTRIBUTED TO EMERGENCY USE AUTHORIZATIONS FOR THREE TREATMENTS, INCLUDING THE MONOCLONAL ANTIBODY THERAPIES FROM BRII BIOSCIENCES, ELI LILLY, AND ASTRAZENECA, AND LED TO AN IMPORTANT CHANGE IN CLINICAL PRACTICE FOR THE USE OF ANTICOAGULATION THERAPIES IN HOSPITALIZED COVID-19 PATIENTS. IMPORTANTLY, ACTIV'S PRIORITIZATION EFFORTS MEANT THAT VALUABLE RESOURCES MONEY, LABORATORY SPACE, HEALTHCARE WORKERS' TIME, AND PATIENTS' HOPES WERE FOCUSED ON THERAPIES LIKELY TO SUCCEED AS COVID-19 TREATMENTS.ACTIV, WHICH INCLUDES EIGHT U.S. GOVERNMENT AGENCIES, FOUR NONPROFIT ORGANIZATIONS, AND 20 INDUSTRY PARTNERS, STANDS OUT AS PERHAPS THE MOST REMARKABLE COLLABORATION TO ARISE FROM THE COVID-19 RESPONSE. ITS FORMATION RELIED ON THE FNIH'S PROVEN PARTNERSHIP MODEL ENGAGE PEOPLE AND ORGANIZATIONS WITH DIVERSE KNOWLEDGE, UNIQUE CAPABILITIES, AND DISTINCT VIEWPOINTS AND CREATE AN ENVIRONMENT BASED ON OBJECTIVE SCIENCE WHERE TRUST AND THE EXCHANGE OF NEW IDEAS CAN THRIVE WHILE ACHIEVING ITS GOALS WITH UNPRECEDENTED SCALE AND SPEED. IT'S A BLUEPRINT THAT THE FNIH WILL CONTINUE TO FOLLOW TO TACKLE A HOST OF DIFFICULT BIOMEDICAL CHALLENGES STEMMING FROM THE CURRENT PANDEMIC AND MANY FUTURE CHALLENGES TO HUMAN HEALTH. TRACEIN EARLY 2020, SCIENTISTS AT THE NIH AND AROUND THE WORLD QUICKLY HAD SEQUENCED THE NEW SARS-COV-2 VIRUS AND HAD BEGUN TO CREATE EFFECTIVE TOOLS FOR STOPPING IT. BUT THEN CAME THE BETA VARIANT. GAMMA, DELTA, AND, MOST RECENTLY, OMICRON VARIANTS FOLLOWED. EACH SUCCESSIVE WAVE OF THE CORONAVIRUS CAUSED DEATH AND DISRUPTION ACROSS THE GLOBE AND THREATENED TO DIMINISH THE EFFECTIVENESS OF NEWLY AVAILABLE COVID-19 VACCINES AND THERAPIES.THE URGENCY OF TRACKING AND STUDYING THESE VARIANTS BECAME PAINFULLY CLEAR. WHILE A VARIETY OF PLATFORMS WERE AND CONTINUE TO BE USED BY DIFFERENT COUNTRIES TO SEQUENCE AND SHARE VIRUS DATA, THE FNIH AND NIH RECOGNIZED EARLY ON THAT A COORDINATED, GLOBAL PERSPECTIVE IS ESSENTIAL TO UNDERSTAND THE EVOLUTION OF THE VIRUS AND THE IMPACT OF VARIANTS ON THERAPEUTICS AND VACCINES. IN JANUARY 2021, THE FNIH CONVENED GOVERNMENT AGENCIES, ACADEMICS, AND PRIVATE PARTNERS TO ESTABLISH THE ACTIV TRACKING RESISTANCE AND CORONAVIRUS EVOLUTION (TRACE) INITIATIVE. THROUGH GENOMIC SURVEILLANCE, DATA SHARING, AND ASSESSMENTS OF TREATMENT RESPONSES TO NEW VIRUS STRAINS, TRACE STANDARDIZES AND CONSOLIDATES DATA FROM GENETIC DATABASES WORLDWIDE TO MONITOR AND TEST COVID-19 VARIANTS. TRACE ALSO ASSESSES VACCINE AND THERAPEUTIC RESISTANCE AND EVALUATES THE IMPACT OF GENETIC VARIATION ON VIRAL BIOLOGY AND ON THE CLINICAL APPROACHES FOR PREVENTING AND TREATING ILLNESS. TRACE HAS SUCCESSFULLY COMPILED ALL OF THIS CRITICAL INFORMATION INTO ONE CLEAR, PUBLICLY ACCESSIBLE PLATFORM AT THE NIH'S NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES AND IS RAPIDLY SHARING DATA ON COVID-19 VARIANTS WITH THE ENTIRE GLOBAL SCIENTIFIC COMMUNITY. THE BESPOKE GENE THERAPY CONSORTIUMRARE DISEASES ARE DEFINED IN THE U.S. AS THOSE THAT AFFECT FEWER THAN 200,000 PEOPLE WITH SOME AFFLICTING AS FEW AS 10 INDIVIDUALS IN THE WORLD. BUT COLLECTIVELY THESE DISEASES ARE RESPONSIBLE FOR WIDESPREAD HARM. SOME 25 TO 30 MILLION AMERICANS, AS WELL AS THEIR FAMILIES AND COMMUNITIES, SUFFER FROM THE APPROXIMATELY 7,000 RARE DISEASES KNOWN TODAY, WITH FEW EFFECTIVE TREATMENTS. ONE TYPE OF TREATMENT HAS EMERGED THAT OFFERS HOPE: GENE THERAPY, A PROCESS THAT REPLACES DEFECTIVE GENES THAT CAUSE DISEASE WITH FUNCTIONAL ONES. WHILE GENE THERAPIES HAVE BEEN SUCCESSFULLY USED TO TREAT COMMON GENETIC DISEASES, THEY CAN ALSO BE TAILORED (OR "BESPOKE") FOR MUCH SMALLER POPULATIONS. DEVELOPING THESE THERAPIES, HOWEVER, IS COMPLEX AND OFTEN EXPENSIVE, AND SMALL PATIENT POPULATIONS MAKE IT CHALLENGING TO GET AN ADEQUATE RETURN ON INVESTMENT IN THE DEVELOPMENT PROCESS. THE BESPOKE GENE THERAPY CONSORTIUM (BGTC) PROMISES TO CHANGE THE PLAYING FIELD FOR GENE THERAPY DEVELOPMENT. LAUNCHED IN LATE 2021 BY THE FNIH, NIH, AND FDA, THE BGTC AIMS TO GENERATE A STANDARDIZED "PLUG-AND-PLAY" TEMPLATE THAT MAKES IT EASIER TO DEVELOP NEW GENE THERAPIES. RATHER THAN CREATING A CUSTOM THERAPY FOR EACH DISEASE FROM SCRATCH, DEVELOPERS COULD SOON BE ABLE TO USE AND REUSE THIS COMMON TEMPLATE TO PRODUCE THERAPIES MORE QUICKLY AND AT LOWER COST. THE BGTC IS THE LATEST INITIATIVE TO EMERGE FROM THE FNIH'S HIGHLY SUCCESSFUL ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAM. BUILDING ON THE AMP COLLABORATION MODEL, THE BGTC PROGRAM BRINGS TOGETHER 30 PUBLIC AND PRIVATE SECTOR ORGANIZATIONS, INCLUDING MANY RARE DISEASE PATIENT GROUPS, TO SUPPORT A SERIES OF RESEARCH PROJECTS AND CLINICAL TRIALS INTENDED TO REFINE AND STANDARDIZE TRIAL DESIGN, REGULATORY EVALUATION, AND MANUFACTURING PROCESSES, ENABLING THE FIELD TO DELIVER MORE VIABLE TREATMENTS FOR RARE DISEASES TO MORE PATIENTS.ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAMSTHE FNIH LAUNCHED THE FIRST THREE ACCELERATING MEDICINES PARTNERSHIP PROGRAMS TOGETHER WITH THE NIH IN 2014. FOCUSED ON ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND RHEUMATOID ARTHRITIS AND LUPUS, THE FIRST AMP PROGRAMS GENERATED GENOMIC AND MOLECULAR DATA AND ANALYTICAL APPROACHES THAT HAVE SUBSTANTIALLY ADVANCED OUR UNDERSTANDING OF DRUG TARGETS IN THESE DISEASES. THESE THREE PARTNERSHIPS HAVE PROVED SO SUCCESSFUL THAT EACH HAS NOT ONLY PRODUCED FOLLOW-ON EFFORTS THAT CONSIDERABLY EXPAND THEIR ORIGINAL RESEARCH AGENDAS, BUT THEY HAVE ALSO INSPIRED COMPLETELY NEW AMP PROGRAMS IN PARKINSON'S DISEASE, SCHIZOPHRENIA, AND GENE THERAPIES.ACCELERATING MEDICINES PARTNERSHIP AND AMP ARE REGISTERED SERVICE MARKS OF THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.NON-INVASIVE BIOMARKERS OF METABOLIC LIVER DISEASE (NIMBLE)NON-ALCOHOLIC STEATOHEPATITIS (NASH) IS A SERIOUS LIVER DISEASE ESTIMATED TO AFFECT BETWEEN 9 AND 15 MILLION PEOPLE IN THE U.S. THE DISEASE OFTEN REMAINS UNDIAGNOSED IN ITS EARLY STAGES AND CAN REQUIRE A LIVER TRANSPLANT OR CAUSE LIVER CANCER AND ULTIMATELY DEATH. CURRENTLY, DIAGNOSING EARLY-STAGE NASH REQUIRES A LIVER BIOPSY, A PAINFUL, INVASIVE, AND EXPENSIVE PROCESS.IN NOVEMBER 2021, THE FNIH BIOMARKERS CONSORTIUM RELEASED THE INITIAL RESULTS FROM ITS NIMBLE PROJECT, WHICH SEEKS TO ASSESS THE SUITABILITY OF SEVERAL NON-INVASIVE, BLOOD-BASED BIOMARKERS FOR USE IN CLINICAL TRIALS OF TREATMENTS FOR NASH. SEVERAL OF THESE BIOMARKERS DID A BETTER JOB OF IDENTIFYING PATIENTS AT RISK OF DEVELOPING NASH OR PROGRESSING TO CIRRHOSIS THAN CURRENT STANDARD TESTS AND COMPARED FAVORABLY WITH THE DIAGNOSTIC PERFORMANCE OF LIVER BIOPSY, THE CURRENT REFERENCE STANDARD. ALTHOUGH FURTHER CONFIRMATORY STUDY MAY BE REQUIRED, THE NEW BIOMARKERS EXAMINED BY NIMBLE COULD POTENTIALLY REPLACE THE NEED FOR PATIENTS WHO HAVE OR WHO MAY BE AT RISK FOR NASH TO UNDERGO BIOPSIES. IF APPROVED BY THE FDA, TESTS USING THESE NEW MARKERS COULD ENABLE EARLY AND ACCURATE DIAGNOSIS OF AT-RISK PATIENTS, IMPROVING THE QUALITY OF CARE, ACCELERATING DRUG DEVELOPMENT, AND REDUCING THE BURDEN IMPOSED BY CURRENT CLINICAL CARE PRACTICES.
4b
(Code:
) (Expenses $
1,310,343
including grants of $
1,011,545
) (Revenue $
)
SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMSPROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - ONE OF THE MANY WAYS THE FNIH ACCELERATES PROGRESS IS THROUGH INVESTMENT IN THE CREATIVITY OF EXCEPTIONAL SCIENTISTS. THE ORGANIZATION BESTOWS THREE PRIZES EACH YEAR TO RECOGNIZE OUTSTANDING PARTNERS AND CONTRIBUTORS TO ADVANCING BIOMEDICAL RESEARCH. 2021 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCESTHE LURIE PRIZE IN BIOMEDICAL SCIENCES IS AN ANNUAL AWARD GIVEN TO PROMISING YOUNGER INVESTIGATORS WHO HAVE ACHIEVED GROUNDBREAKING ADVANCES IN BIOMEDICAL SCIENCE. THE PRIZE IS MADE POSSIBLE BY A GENEROUS GIFT FROM NOTED PHILANTHROPIST AND FNIH HONORARY BOARD MEMBER ANN LURIE. IN 2021, THE FNIH HONORED XIAOWEI ZHUANG, PH.D., FOR HER REVOLUTIONARY WORK DEVELOPING SUPER-RESOLUTION MICROSCOPY AND GENOME-SCALE IMAGING THAT REVEALED NEW SPATIAL AND FUNCTIONAL ORGANIZATIONS OF MOLECULES AND CELLS. DR. ZHUANG'S INNOVATIVE WORK WITH MICROSCOPY HAS ENABLED RESEARCHERS TO VISUALIZE WITH HIGH RESOLUTION THE POSITIONING OF AND INTERACTIONS BETWEEN MOLECULES IN A CELL, AS WELL AS THE SPATIAL ORGANIZATION OF DISTINCT TYPES OF CELLS IN TISSUES. HER DISCOVERIES HAVE MADE A SIGNIFICANT IMPACT ACROSS THE FIELD OF BIOLOGY, WITH SEMINAL APPLICATIONS TO CELL BIOLOGY.DR. ZHUANG IS A PROFESSOR AT HARVARD UNIVERSITY, A HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR, AND CO-FOUNDER OF THE LIFE SCIENCES COMPANY VIZGEN.TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTSTHE TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTS WAS ESTABLISHED IN 2018 TO HIGHLIGHT THE ESSENTIAL ROLE OF EARLY CAREER CLINICIAN-SCIENTISTS WHOSE RESEARCH HAS LED OR HAS THE POTENTIAL TO LEAD TO INNOVATIONS IN PATIENT CARE.IN 2021, PIRO LITO, M.D., PH.D., ASSOCIATE MEMBER AND ATTENDING PHYSICIAN AT MEMORIAL SLOAN KETTERING CANCER CENTER, WAS AWARDED THE PRIZE FOR CATALYZING BREAKTHROUGHS IN THE UNDERSTANDING OF ONCOPROTEIN SIGNALING AND THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES FOR CANCERS DRIVEN BY THE MUTANT KRAS PROTEIN.WORKING AT THE INTERFACE OF BASIC RESEARCH AND CLINICAL PRACTICE, DR. LITO STUDIES HOW MUTATED PROTEINS DRIVE TUMOR GROWTH. HE IS PARTICULARLY INTERESTED IN A PROTEIN CALLED KRAS, WHICH IS COMMONLY MUTATED IN LUNG, COLORECTAL, AND PANCREATIC CANCERS. DR. LITO HAS UNCOVERED HOW MUTANT KRAS TRANSITIONS BETWEEN ITS ACTIVE AND INACTIVE STATES IN CANCER CELLS AND, BY EXPOSING VULNERABLE EVENTS DURING THIS TRANSITION, HE HAS MADE KEY CONTRIBUTIONS TO THE DEVELOPMENT OF NOVEL CANCER THERAPIES THAT ARE CURRENTLY IN CLINICAL TRIALS.FUNDING FOR THE TRAILBLAZER PRIZE IS PROVIDED BY THE GALLIN FUND AT THE FNIH.CHARLES A. SANDERS, M.D., PARTNERSHIP AWARDEACH YEAR, THE FNIH BESTOWS THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD TO RECOGNIZE PEOPLE OR ORGANIZATIONS THAT HAVE MADE PARTICULARLY SIGNIFICANT CONTRIBUTIONS TO THE FOUNDATION'S EFFORTS TO BUILD, IMPLEMENT, AND NURTURE PUBLIC-PRIVATE PARTNERSHIPS IN SUPPORT OF THE MISSION OF THE NIH.IN 2021, THE FNIH PRESENTED THE PARTNERSHIP AWARD TO JANSSEN RESEARCH & DEVELOPMENT, LLC, AND TO THE EIGHT CO-CHAIRS OF THE ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) WORKING GROUPS.JANSSEN RESEARCH & DEVELOPMENT, LLC, HAS BEEN AN EXEMPLARY PARTNER AND LEADER ACROSS MANY FNIH PROGRAMS, INCLUDING ACTIV, SEVERAL ACCELERATING MEDICINES PARTNERSHIPS, THE BIOMARKERS CONSORTIUM, THE PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT), AND THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI). THE MANY JANSSEN SCIENTISTS WHO HAVE PARTICIPATED IN THESE PARTNERSHIPS HAVE CONSISTENTLY PROMOTED A HIGHLY COLLEGIAL, COLLABORATIVE APPROACH TO PROBLEM-SOLVING WITH AN EMPHASIS ON TEAMWORK AND TRANSPARENT COMMUNICATION THAT ENABLES OPEN, PRECOMPETITIVE SCIENCE.IN SUPPORT OF FINDING THERAPEUTICS AND VACCINES TO COMBAT COVID-19, THE ACTIV WORKING GROUP CO-CHAIRS SPENT COUNTLESS HOURS COLLABORATING WITH THE FNIH AND NIH TO DESIGN STRATEGIES FOR COMBATING THE COVID-19 PANDEMIC AND EXECUTE THEM WITH UNPRECEDENTED SPEED. THEY PARTICIPATED IN HUNDREDS OF MEETINGS, REPORTING REGULARLY TO THE ACTIV LEADERSHIP TEAM, AND DEVOTED VALUABLE TIME AND EFFORT TO IDENTIFY OPPORTUNITIES FOR AND HELP RESOLVE CHALLENGES TO THE PARTNERSHIP. THEIR ALL-OUT EFFORTS WERE ESSENTIAL TO ENABLING ACTIV TO NAVIGATE THE RAPIDLY CHANGING NATURE OF THE THREATS TO GLOBAL HUMAN HEALTH POSED BY SARS-COV-2.THE CO-CHAIRS OF THE ACTIV WORKING GROUPS:CHRISTINE M. COLVIS, PH.D., DIRECTOR OF DRUG DEVELOPMENT PARTNERSHIP PROGRAMS, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIHELIZABETH DESROSIERS, M.S., P.M.P., EXECUTIVE DIRECTOR OF CLINICAL SCIENCES AND STUDY MANAGEMENT AT MERCK & CO., INC.ERIC HUGHES, M.D., PH.D., GLOBAL DEVELOPMENT UNIT HEAD OF IMMUNOLOGY, HEPATOLOGY AND DERMATOLOGY, AND CHI-NOVARTISKATHRIN JANSEN, PH.D., SENIOR VICE PRESIDENT AND HEAD OF VACCINE RESEARCH AND DEVELOPMENT AT PFIZERMICHAEL KURILLA, M.D., PH.D., DIRECTOR, DIVISION OF CLINICAL INNOVATION, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIHDOUGLAS LOWY, M.D., PRINCIPAL DEPUTY DIRECTOR, NATIONAL CANCER INSTITUTE (NCI) AT NIHSARAH READ, M.D., DEPUTY DIRECTOR, DIVISION OF AIDS, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) AT NIH JOHN YOUNG, PH.D., GLOBAL HEAD OF INFECTIOUS DISEASES AND VICE PRESIDENT AT ROCHEFUNDING FOR THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD IS PROVIDED BY THE CHARLES A. SANDERS LEGACY FUND AT THE FNIH.EVENTS AND EDUCATIONTHE MEETINGS AND EVENTS DEPARTMENT CONCEPTUALIZES, PLANS, EXECUTES AND EVALUATES HIGH-QUALITY, PRODUCTIVE, INNOVATIVE AND ECONOMICAL CONVENINGS THAT ADVANCE THE ORGANIZATION'S MISSION. THESE CONVENINGS INCLUDE, BUT ARE NOT LIMITED TO, RESEARCH PROJECT TEAM MEETINGS AND CONFERENCES, DONOR STEWARDSHIP LECTURES AND SYMPOSIA AND SPECIAL EVENTS. THE DEPARTMENT OVERSEES THE MANAGEMENT OF FNIH HIGHLY RESPECTED AWARDS AND PRIZES. SOME OF THE FNIH'S MARQUEE EVENTS IN 2021 INCLUDED: THE FNIH AWARDS CEREMONY, THE CANCER STEERING COMMITTEE'S ANNUAL SYMPOSIUM, AND THE GENECONVENE GLOBAL COLLABORATIVE WEBINARS SERIES.THE FNIH SUPPORTS A NUMBER OF EDUCATIONAL AND TRAINING OPPORTUNITIES AT NIH, RANGING FROM HIGH SCHOOL TO POSTGRADUATE FELLOWSHIPS AND TRAINING. MANY OF THESE FELLOWSHIPS AND TRAININGS ARE ESTABLISHED BY INDIVIDUALS WHO SEEK TO SUPPORT THE NEXT GENERATION OF SCIENTISTS. EXAMPLES INCLUDE:- THE JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH AND POLICY SUPPORTS INTRAMURAL RESEARCH TRAINING AWARDS FOR DESERVING YOUNG SCHOLARS IN THE NIH INTRAMURAL TRAINING PROGRAM.- THE DEAN R. O'NEILL RENAL CELL CANCER RESEARCH FUND AND THE DR. EDWARD T. RANCIC MEMORIAL FUND FOR CANCER RESEARCH JOINTLY SUPPORT A FELLOW IN THE LABORATORY OF DR. RICHARD CHILDS AT THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE TO EXPLORE TREATMENTS FOR RENAL CELL CARCINOMA.- THE ESTATE OF SALLIE ROSEN KAPLAN ESTABLISHED THE SALLIE ROSEN KAPLAN POSTDOCTORAL FELLOWSHIP FOR WOMEN SCIENTISTS IN CANCER RESEARCH (SRK FELLOWSHIP). THE SRK FELLOWSHIP IS A HIGHLY COMPETITIVE, UNPAID, ANNUAL, ONE-YEAR PROGRAM THAT PROVIDES ADDITIONAL MENTORING OPPORTUNITIES, NETWORKING, SEMINARS AND WORKSHOPS TO FEMALE NATIONAL CANCER INSTITUTE POSTDOCTORAL FELLOWS TO HELP THEM PREPARE FOR THE COMPETITIVE JOB MARKET AND HELP THEM TO TRANSITION TO INDEPENDENT RESEARCH CAREERS.
4c
(Code:
) (Expenses $
53,512
including grants of $
0
) (Revenue $
0
)
SEE SCHEDULE O, PROGRAM THREE, PATIENT SUPPORT PROGRAM/CAPITAL PROJECTPROGRAM THREE - PATIENT SUPPORT PROGRAM/CAPITAL PROJECT -FILLING A NEED OF THE NATION'S LEADING RESEARCH CENTERAT THE NIH CLINICAL CENTER THE NATION'S PREMIER HOSPITAL SOLELY DEVOTED TO CLINICAL INVESTIGATION PATIENTS ARE CONSIDERED "ACTIVE PARTNERS IN MEDICAL DISCOVERY," PARTICIPATING IN EXPERIMENTAL TRIALS CARRIED OUT BY NIH INSTITUTES TO RECEIVE TREATMENT FOR THEIR CONDITIONS AND ULTIMATELY BENEFIT SCIENTIFIC PROGRESS. THE EXTENSIVE LIST OF RESEARCH BREAKTHROUGHS COMING OUT OF THE NIH CLINICAL CENTER INCLUDES THE FIRST CURES FOR CHILDHOOD LEUKEMIA AND HODGKIN'S DISEASE USING CHEMOTHERAPY, THE FIRST BLOOD TESTS FOR AIDS AND HEPATITIS, AND THE FIRST GENE THERAPY, TO NAME JUST A FEW. TO SUPPORT SUCH RESOURCE-INTENSIVE ENDEAVORS, THE FNIH ESTABLISHED THE CLINICAL CENTER IN-KIND DRUG DONATION PROGRAM TO DONATE PHARMACEUTICALS TO THE NIH CLINICAL CENTER. THE PROGRAM, WHICH HAS PROVIDED NEARLY $16 MILLION IN DRUGS AND THERAPEUTICS TO THE NIH SINCE 2008, WAS SUPPORTED IN 2019 BY A MAJOR GIFT FROM HORIZON THERAPEUTICS PLC. "THE GENEROSITY OF THE PROGRAM HAS BEEN A MAJOR BOON TO OUR PATIENTS AND OUR PROGRAM," SAYS DR. STEVEN HOLLAND, DIRECTOR, DIVISION OF INTRAMURAL RESEARCH AT NIAID.
4d
Other program services (Describe in Schedule O.)
(Expenses $
including grants of $
) (Revenue $
)
4e
Total program service expenses
51,956,043
Form
990
(2021)
Form 990 (2021)
Page
3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?
If "Yes," complete Schedule A
.....................
1
Yes
2
Is the organization required to complete
Schedule B, Schedule of Contributors
? See instructions.
...
2
Yes
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office?
If "Yes," complete Schedule C,
Part I
.............
3
No
4
Section 501(c)(3) organizations.
Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year?
If "Yes," complete Schedule C,
Part II
.........
4
Yes
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Rev. Proc. 98-19?
If "Yes," complete Schedule C,
Part III
..
5
No
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts?
If "Yes," complete
Schedule D,
Part I
.........................
6
Yes
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas, or historic structures?
If "Yes," complete Schedule D,
Part II
....
7
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets?
If "Yes,"
complete Schedule D,
Part III
..............
8
No
9
Did the organization report an amount in
Part X
, line 21 for escrow or custodial account liability; serve as a custodian for amounts not listed in
Part X
; or provide credit counseling, debt management, credit repair, or debt negotiation services?
If "Yes," complete Schedule D,
Part IV
..............
9
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi endowments?
If "Yes," complete Schedule D,
Part V
......
10
Yes
11
If the organization’s answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X, as applicable.
a
Did the organization report an amount for land, buildings, and equipment in
Part X
, line 10?
If "Yes," complete
Schedule D,
Part VI
.
...................
11a
Yes
b
Did the organization report an amount for investments—other securities in
Part X
, line 12 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VII
.......
11b
No
c
Did the organization report an amount for investments—program related in
Part X
, line 13 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VIII
.......
11c
No
d
Did the organization report an amount for other assets in
Part X
, line 15 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part IX
............
11d
No
e
Did the organization report an amount for other liabilities in
Part X
, line 25?
If "Yes," complete Schedule D,
Part X
11e
Yes
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)?
If "Yes," complete Schedule D,
Part X
11f
Yes
12a
Did the organization obtain separate, independent audited financial statements for the tax year?
If "Yes," complete
Schedule D, Parts XI and XII
......................
12a
Yes
b
Was the organization included in consolidated, independent audited financial statements for the tax year?
If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional
12b
No
13
Is the organization a school described in section 170(b)(1)(A)(ii)?
If "Yes," complete Schedule E
13
No
14a
Did the organization maintain an office, employees, or agents outside of the United States?
.....
14a
No
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more?
If "Yes," complete Schedule F, Parts I and IV
.........
14b
Yes
15
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization?
If “Yes,” complete Schedule F, Parts II and IV
.....
15
Yes
16
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals?
If “Yes,” complete Schedule F, Parts III and IV
...
16
No
17
Did the organization report a total of more than $15,000 of expenses for professional fundraising services on
Part IX
, column (A), lines 6 and 11e?
If "Yes," complete Schedule G,
Part I.
See instructions.
....
17
No
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on
Part VIII
, lines 1c and 8a?
If "Yes," complete Schedule G,
Part II
............
18
Yes
19
Did the organization report more than $15,000 of gross income from gaming activities on
Part VIII
, line 9a?
If "Yes," complete Schedule G,
Part III
...................
19
No
20a
Did the organization operate one or more hospital facilities?
If "Yes," complete Schedule H
....
20a
No
b
If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?
20b
21
Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on
Part IX
, column (A), line 1?
If “Yes,” complete Schedule I, Parts I and II
.....
21
Yes
Form
990
(2021)
Form 990 (2021)
Page
4
Part IV
Checklist of Required Schedules
(continued)
Yes
No
22
Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on
Part IX
, column (A), line 2?
If “Yes,” complete Schedule I, Parts I and III
........
22
Yes
23
Did the organization answer "Yes" to
Part VII
, Section A, line 3, 4, or 5, about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees?
If "Yes," complete Schedule J
.......................
23
Yes
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002?
If “Yes,” answer lines 24b through 24d and complete Schedule K. If “No,” go to line 25a
...............
24a
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?
...
24b
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds?
...............
24c
d
Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?
...
24d
25a
Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.
Did the organization engage in an excess benefit transaction with a disqualified person during the year?
If "Yes," complete Schedule L,
Part I
....
25a
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ?
If "Yes," complete Schedule L,
Part I
.......................
25b
No
26
Did the organization report any amount on Part X, line 5 or 22 for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons?
If "Yes," complete Schedule L,
Part II
...........
26
No
27
Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons?
If "Yes," complete
Schedule L,
Part III
.........................
27
No
28
Was the organization a party to a business transaction with one of the following parties (see the Schedule L,
Part IV
instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor?
If "Yes," complete Schedule L,
Part IV
......................
28a
No
b
A family member of any individual described in line 28a?
If "Yes," complete Schedule L,
Part IV
.....
28b
No
c
A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b?
If "Yes," complete Schedule L,
Part IV
.....................
28c
No
29
Did the organization receive more than $25,000 in non-cash contributions?
If "Yes," complete Schedule M
..
29
Yes
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions?
If "Yes," complete Schedule M
.................
30
No
31
Did the organization liquidate, terminate, or dissolve and cease operations?
If "Yes," complete Schedule N,
Part I
31
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets?
If "Yes," complete Schedule N,
Part II
........................
32
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3?
If "Yes," complete Schedule R,
Part I
............
33
No
34
Was the organization related to any tax-exempt or taxable entity?
If "Yes," complete Schedule R,
Part II
, III, or IV, and
Part V
, line 1
.........................
34
No
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
No
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)?
If "Yes," complete Schedule R,
Part V
, line 2
...
35b
36
Section 501(c)(3) organizations.
Did the organization make any transfers to an exempt non-charitable related organization?
If "Yes," complete Schedule R,
Part V
, line 2
.............
36
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes?
If "Yes," complete Schedule R,
Part VI
37
No
38
Did the organization complete Schedule O and provide explanations on Schedule O for
Part VI
, lines 11b and 19?
Note.
All Form 990 filers are required to complete Schedule O.
............
38
Yes
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response or note to any line in this
Part V
...........
Yes
No
1a
Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable
..
1a
35
b
Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable
.
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?
..................
1c
Yes
Form
990
(2021)
Form 990 (2021)
Page
5
Part V
Statements Regarding Other IRS Filings and Tax Compliance
(continued)
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and
Tax Statements, filed for the calendar year ending with or within the year covered by this return
..................
2a
86
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?
Note.
If the sum of lines 1a and 2a is greater than 250, you may be required to e-file. See instructions.
2b
Yes
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?
...
3a
No
b
If “Yes,” has it filed a Form 990-T for this year?
If “No” to line 3b, provide an explanation in Schedule O
...
3b
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?
..
4a
No
b
If "Yes," enter the name of the foreign country:
See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?
..
5a
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
No
c
If "Yes," to line 5a or 5b, did the organization file Form 8886-T?
............
5c
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?
...
6a
No
b
If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?
......................
6b
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?
....................
7a
Yes
b
If "Yes," did the organization notify the donor of the value of the goods or services provided?
.....
7b
Yes
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?
.........................
7c
No
d
If "Yes," indicate the number of Forms 8282 filed during the year
....
7d
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?
7e
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?
..
7f
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?
......................
7g
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?
..........................
7h
8
Sponsoring organizations maintaining donor advised funds.
Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?
........
8
9
Sponsoring organizations maintaining donor advised funds.
a
Did the sponsoring organization make any taxable distributions under section 4966?
........
9a
b
Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?
...
9b
10
Section 501(c)(7) organizations.
Enter:
a
Initiation fees and capital contributions included on
Part VIII
, line 12
...
10a
b
Gross receipts, included on Form 990,
Part VIII
, line 12, for public use of club facilities
10b
11
Section 501(c)(12) organizations.
Enter:
a
Gross income from members or shareholders
.........
11a
b
Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.)
..........
11b
12a
Section 4947(a)(1) non-exempt charitable trusts.
Is the organization filing Form 990 in lieu of Form 1041?
12a
b
If "Yes," enter the amount of tax-exempt interest received or accrued during the year.
12b
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state?
.........
Note.
See the instructions for additional information the organization must report on Schedule O.
13a
b
Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans
....
13b
c
Enter the amount of reserves on hand
............
13c
14a
Did the organization receive any payments for indoor tanning services during the tax year?
.....
14a
No
b
If "Yes," has it filed a Form 720 to report these payments?
If "No," provide an explanation in Schedule O
..
14b
15
Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year?
....................
If "Yes," see the instructions and file Form 4720, Schedule N.
15
No
16
Is the organization an educational institution subject to the section 4968 excise tax on net investment income?
..
If "Yes," complete Form 4720, Schedule O.
16
No
17
Section 501(c)(21) organizations.
Did the trust, any disqualified person, or mine operator engage in any activities that would result in the imposition of an excise tax under section 4951, 4952, or 4953?
..
If "Yes," complete Form 6069.
17
Form
990
(2021)
Form 990 (2021)
Page
6
Part VI
Governance, Management, and Disclosure.
For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines
8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response or note to any line in this
Part VI
..............
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
1a
24
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
b
Enter the number of voting members included in line 1a, above, who are independent
1b
24
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?
.................
2
Yes
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person?
.
3
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?
.
4
Yes
5
Did the organization become aware during the year of a significant diversion of the organization’s assets?
.
5
No
6
Did the organization have members or stockholders?
................
6
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?
....................
7a
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?
...................
7b
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body?
.......................
8a
Yes
b
Each committee with authority to act on behalf of the governing body?
............
8b
Yes
9
Is there any officer, director, trustee, or key employee listed in
Part VII
, Section A, who cannot be reached at the organization’s mailing address?
If "Yes," provide the names and addresses in Schedule O
.......
9
No
Section B. Policies
(
This Section B requests information about policies not required by the Internal Revenue Code.
)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates?
............
10a
No
b
If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?
10b
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?
............................
11a
Yes
b
Describe on Schedule O the process, if any, used by the organization to review this Form 990.
.....
12a
Did the organization have a written conflict of interest policy?
If "No," go to line 13
.......
12a
Yes
b
Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?
..........................
12b
Yes
c
Did the organization regularly and consistently monitor and enforce compliance with the policy?
If "Yes," describe on Schedule O how this was done
...................
12c
Yes
13
Did the organization have a written whistleblower policy?
...............
13
Yes
14
Did the organization have a written document retention and destruction policy?
.........
14
Yes
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official
...........
15a
Yes
b
Other officers or key employees of the organization
................
15b
Yes
If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?
......................
16a
No
b
If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements?
............
16b
Section C. Disclosure
17
List the states with which a copy of this Form 990 is required to be filed
MD
,
VA
,
NY
,
AL
,
AR
,
CA
,
FL
,
GA
,
HI
,
IL
,
KS
,
KY
,
MA
,
MI
,
MS
,
MN
,
NH
,
NJ
,
NM
,
OR
,
PA
,
RI
,
SC
,
TN
,
UT
,
WV
,
WI
18
Section 6104 requires an organization to make its Form 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
Own website
Another's website
Upon request
Other (explain in Schedule O)
19
Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, address, and telephone number of the person who possesses the organization's books and records:
DONALD M HILL
11400 ROCKVILLE PIKE SUITE 600
NORTH BETHESDA
,
MD
20852
(301) 435-6246
Form
990
(2021)
Form 990 (2021)
Page
7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response or note to any line in this
Part VII
..............
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a
Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
List all of the organization’s
current
officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
List all of the organization’s
current
key employees, if any. See the instructions for definition of "key employee."
List the organization’s five
current
highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (box 5 of Form W-2, Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than $100,000 from the
organization and any related organizations.
List all of the organization’s
former
officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.
List all of the organization’s
former directors or trustees
that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.
See the instructions for the order in which to list the persons above.
Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(F)
Estimated amount of other compensation from the organization and related organizations
(1)
DR STEVEN M PAUL
......................................................................
CHAIRMAN
1.50
.................
X
X
0
0
0
(2)
DR SOLOMON H SNYDER
......................................................................
VICE-CHAIRMAN
0.50
.................
X
X
0
0
0
(3)
MR STEVEN C MAYER
......................................................................
TREASURER
2.00
.................
X
X
0
0
0
(4)
MRS WILLIAM MCCORMICK BLAIR JR
......................................................................
SECRETARY
1.00
.................
X
X
0
0
0
(5)
DR MARIA C FREIRE UNTIL SEPT
......................................................................
PRESIDENT & EXECUTIVE DIRECTOR
40.00
.................
X
X
458,587
0
23,200
(6)
DR KATHY BLOOMGARDEN
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(7)
DR MARIJN DEKKERS
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(8)
MR JAMES H DONOVAN
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(9)
DR PAUL L HERRLING
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(10)
DR THOMAS R INSEL
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(11)
DR JUDY LANSING KOVLER
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(12)
DR RONALD L KRALL
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(13)
DR FREDA LEWIS-HALL
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(14)
JULIE BELL LINDSAY
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(15)
DR EDISON T LIU
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(16)
MR JOEL S MARCUS
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
(17)
DAME JILLIAN SACKLER
......................................................................
BOARD OF DIRECTORS MEMBER
0.50
.................
X
0
0
0
Form
990
(2021)
Form 990 (2021)
Page
8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
(continued)
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(F)
Estimated amount of other compensation from the organization and related organizations
(18)
MRS LILY SAFRA
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(19)
DR CHARLES A SANDERS
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(20)
MR FRED SEIGEL
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(21)
DR ELLEN V SIGAL
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(22)
MR RUSSELL W STEENBERG
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(23)
DR PAUL STOFFELS
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(24)
ELIAS ZERHOUNI
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(25)
GILBERT S OMENN
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(26)
MRS WILLIAM M CAFRITZ UNTIL MAY
........................................................................
BOARD OF DIRECTORS MEMBER
0.50
.......................
X
0
0
0
(27)
DAVID WHOLLEY FROM SEPT
........................................................................
INTERIM PRES. & EXECUTIVE DIRECTOR
40.00
.......................
X
415,304
0
38,260
(28)
DONALD HILL
........................................................................
CHIEF FINANCIAL OFFICER
40.00
.......................
X
264,990
0
36,642
(29)
KEVIN A KLOCK
........................................................................
VP OF OPERATIONS & GENERAL COUNSEL
40.00
.......................
X
236,844
0
34,800
(30)
STEPHANIE JAMES
........................................................................
SENIOR SCIENTIFIC ADVISOR
40.00
.......................
X
285,699
0
22,463
(31)
MICHAEL SANTOS
........................................................................
VICE PRESIDENT OF SCIENCE
40.00
.......................
X
341,916
0
30,380
(32)
JULIE WOLF-RODDA
........................................................................
SENIOR VP OF DEVELOPMENT
40.00
.......................
X
248,167
0
34,493
(33)
JOSEPH MENETSKI
........................................................................
VP, RESEARCH PARTNERSHIPS
40.00
.......................
X
270,098
0
34,092
(34)
ROBERT BALTHASER
........................................................................
VICE PRESIDENT OF ADVANCEMENT
40.00
.......................
X
171,092
0
20,719
(35)
STACEY ADAM
........................................................................
ASSOCIATE VP, RESEARCH PARTNERSHIPS
40.00
.......................
X
235,835
0
25,932
(36)
DAVID O'BROCHTA
........................................................................
SCIENTIFIC PROGRAM MANAGER
40.00
.......................
X
195,268
0
31,019
(37)
KAREN TOUNTAS
........................................................................
SCIENTIFIC PROGRAM MANAGER
40.00
.......................
X
193,750
0
22,492
(38)
BRINDA DASS
........................................................................
SCIENTIFIC PROGRAM MANAGER
40.00
.......................
X
188,862
0
24,049
(39)
STEVEN HOFFMANN
........................................................................
ASSOCIATE VP, RESEARCH PARTNERSHIPS
40.00
.......................
X
187,977
0
27,608
1b
Sub-Total
................
c
Total from continuation sheets to
Part VII
, Section A
....
d
Total (add lines 1b and 1c)
...........
3,694,389
0
406,149
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization
34
Yes
No
3
Did the organization list any
former
officer, director or trustee, key employee, or highest compensated employee on line 1a?
If "Yes," complete Schedule J for such individual
..............
3
No
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000?
If "Yes," complete Schedule J for such
individual
...........................
4
Yes
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization?
If "Yes," complete Schedule J for such person
........
5
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address
(B)
Description of services
(C)
Compensation
SWOG CTI
24 FRANK LLOYD WRIGHT DRIVE PO BOX
ANN ARBOR
,
MI
48105
CLINICAL TRIAL FOR LUNG MAP PROJECT
6,280,530
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE
BOSTON
,
MA
02215
THE PACT & CTDNA RESEARCH COLLABORATION
2,521,758
DELOITTE CONSULTING LLP
4022 SELLS DRIVE
HERMITAGE
,
TN
37076
COVID-19 PROJECT PROFESSIONAL SERVICES
2,382,326
THE UNIVERSITY OF TEXASMD ANDERSON
PO BOX 4266
HOUSTON
,
TX
77210
THE PACT PROJECT RESEARCH COLLABORATION
905,317
THE BROAD INSTITUTE INC
415 MAIN STREET
CAMBRIDGE
,
MA
02142
THE CHIIME PROJECT RESEARCH COLLABORATIO
884,421
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization
32
Form
990
(2021)
Form 990 (2021)
Page
9
Part VIII
Statement of Revenue
Check if Schedule O contains a response or note to any line in this
Part VIII
.............
(A)
Total revenue
(B)
Related or
exempt
function
revenue
(C)
Unrelated
business
revenue
(D)
Revenue
excluded from
tax under sections
512 - 514
1a
Federated campaigns
..
1a
b
Membership dues
..
1b
c
Fundraising events
..
1c
60,500
d
Related organizations
1d
e
Government grants (contributions)
1e
1,250,000
f
All other contributions, gifts, grants, and similar amounts not included above
1f
104,683,285
g
Noncash contributions included in lines 1a - 1f:$
1g
3,684,256
h Total.
Add lines 1a-1f
.......
105,993,785
Business Code
2a
ADMINISTRATIVE REVENUE
900099
50,000
50,000
b
c
d
e
f
All other program service revenue.
g
Total.
Add lines 2a–2f
.....
50,000
3
Investment income (including dividends, interest, and other
similar amounts)
......
1,346,882
1,346,882
4
Income from investment of tax-exempt bond proceeds
5
Royalties
...........
(ii) Personal
(i) Real
6a
Gross rents
6a
b
Less: rental expenses
6b
c
Rental income or (loss)
6c
d
Net rental income or (loss)
.......
(ii) Other
(i) Securities
7a
Gross amount from sales of assets other than inventory
11,955,373
7a
b
Less: cost or other basis and sales expenses
11,778,361
7b
c
Gain or (loss)
177,012
7c
d
Net gain or (loss)
.........
177,012
177,012
8a
Gross income from fundraising events (not including $
60,500
of contributions reported on line 1c).
See
Part IV
, line 18
....
8a
291,800
b
Less: direct expenses
...
8b
253,788
c
Net income or (loss) from fundraising events
..
38,012
38,012
9a
Gross income from gaming activities.
See
Part IV
, line 19
...
9a
b
Less: direct expenses
...
9b
c
Net income or (loss) from gaming activities
..
10a
Gross sales of inventory, less
returns and allowances
..
10a
b
Less: cost of goods sold
..
10b
c
Net income or (loss) from sales of inventory
..
Business Code
Miscellaneous Revenue
11a
b
c
d
All other revenue
....
e
Total.
Add lines 11a–11d
......
12
Total revenue.
See instructions
.....
107,605,691
50,000
0
1,561,906
Form
990
(2021)
Form 990 (2021)
Page
10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).
Check if Schedule O contains a response or note to any line in this
Part IX
..............
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of
Part VIII
.
(A)
Total expenses
(B)
Program service
expenses
(C)
Management and
general expenses
(D)
Fundraising
expenses
1
Grants and other assistance to domestic organizations and domestic governments. See
Part IV
, line 21
....
20,124,066
20,124,066
2
Grants and other assistance to domestic individuals. See
Part IV
, line 22
...........
3,500
3,500
3
Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See
Part IV
, lines 15 and 16.
.............
798,005
798,005
4
Benefits paid to or for members
.......
5
Compensation of current officers, directors, trustees, and key employees
...........
2,967,746
1,436,567
1,482,419
48,760
6
Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)
.........
7
Other salaries and wages
........
5,868,953
3,971,368
1,897,585
8
Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)
....
514,483
309,430
195,960
9,093
9
Other employee benefits
.......
1,231,077
781,689
434,363
15,025
10
Payroll taxes
...........
618,512
317,744
300,768
11
Fees for services (non-employees):
a
Management
......
b
Legal
.........
190,081
87,892
102,189
c
Accounting
...........
d
Lobbying
...........
e
Professional fundraising services.
See
Part IV
, line 17
f
Investment management fees
......
183,504
183,504
g
Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)
12
Advertising and promotion
....
33,712
27,813
5,899
13
Office expenses
.......
10,468
5,871
4,597
14
Information technology
......
121,563
44,439
56,938
20,186
15
Royalties
..
16
Occupancy
...........
735,559
179,582
555,977
17
Travel
............
140,390
134,401
5,989
18
Payments of travel or entertainment expenses for any federal, state, or local public officials
.
19
Conferences, conventions, and meetings
....
20
Interest
...........
21
Payments to affiliates
.......
22
Depreciation, depletion, and amortization
..
240,478
240,478
23
Insurance
...
228,032
135,102
92,930
24
Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a
PROGRAM CONTRACTS
19,091,057
19,078,577
12,480
b
CONSULTANTS
4,655,198
4,311,705
326,029
17,464
c
RECRUITING
379,759
30,625
349,134
d
HONORARIA
112,000
112,000
e
All other expenses
154,493
65,667
87,084
1,742
25
Total functional expenses.
Add lines 1 through 24e
58,402,636
51,956,043
6,334,323
112,270
26
Joint costs.
Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation.
Check here
if following SOP 98-2 (ASC 958-720).
Form
990
(2021)
Form 990 (2021)
Page
11
Part X
Balance Sheet
Check if Schedule O contains a response or note to any line in this
Part IX
..............
(A)
Beginning of year
(B)
End of year
1
Cash–non-interest-bearing
........
1
2
Savings and temporary cash investments
.........
66,486,739
2
47,993,053
3
Pledges and grants receivable, net
......
41,358,911
3
67,125,693
4
Accounts receivable, net
.............
4
5
Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.......
5
6
Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)
...
6
7
Notes and loans receivable, net
...........
7
8
Inventories for sale or use
............
8
9
Prepaid expenses and deferred charges
......
235,751
9
230,354
10a
Land, buildings, and equipment: cost or other basis. Complete
Part VI
of Schedule D
10a
2,965,720
b
Less: accumulated depreciation
10b
1,239,951
1,948,833
10c
1,725,769
11
Investments—publicly traded securities
.
59,636,280
11
101,529,635
12
Investments—other securities. See
Part IV
, line 11
.....
12
13
Investments—program-related. See
Part IV
, line 11
..
13
14
Intangible assets
...............
14
15
Other assets. See
Part IV
, line 11
...........
2,273,227
15
3,335,255
16
Total assets.
Add lines 1 through 15 (must equal line 33)
...
171,939,741
16
221,939,759
17
Accounts payable and accrued expenses
.....
7,166,950
17
8,537,356
18
Grants payable
...
18
19
Deferred revenue
.........
1,331,478
19
338,978
20
Tax-exempt bond liabilities
.........
20
21
Escrow or custodial account liability.
Complete
Part IV
of Schedule D
21
22
Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.........
22
23
Secured mortgages and notes payable to unrelated third parties
..
23
24
Unsecured notes and loans payable to unrelated third parties
..
24
25
Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24).
Complete
Part X
of Schedule D
2,237,097
25
2,114,103
26
Total liabilities.
Add lines 17 through 25
..
10,735,525
26
10,990,437
Organizations that follow FASB ASC 958,
check here
and complete lines 27, 28, 32, and 33.
27
Net assets without donor restrictions
..........
25,368,465
27
28,544,211
28
Net assets with donor restrictions
...........
135,835,751
28
182,405,111
Organizations that do not follow FASB ASC 958,
check here
and complete lines 29 through 33.
29
Capital stock or trust principal, or current funds
.....
29
30
Paid-in or capital surplus, or land, building or equipment fund
...
30
31
Retained earnings, endowment, accumulated income, or other funds
31
32
Total net assets or fund balances
...........
161,204,216
32
210,949,322
33
Total liabilities and net assets/fund balances
........
171,939,741
33
221,939,759
Form
990
(2021)
Form 990 (2021)
Page
12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response or note to any line in this
Part XI
..............
1
Total revenue (must equal
Part VIII
, column (A), line 12)
............
1
107,605,691
2
Total expenses (must equal
Part IX
, column (A), line 25)
............
2
58,402,636
3
Revenue less expenses. Subtract line 2 from line 1
..............
3
49,203,055
4
Net assets or fund balances at beginning of year (must equal
Part X
, line 32, column (A))
..
4
161,204,216
5
Net unrealized gains (losses) on investments
...............
5
542,051
6
Donated services and use of facilities
.................
6
7
Investment expenses
.....................
7
8
Prior period adjustments
.....................
8
9
Other changes in net assets or fund balances (explain in Schedule O)
........
9
0
10
Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal
Part X
, line 32, column (B))
10
210,949,322
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response or note to any line in this
Part XII
.............
Yes
No
1
Accounting method used to prepare the Form 990:
Cash
Accrual
Other
If the organization changed its method of accounting from a prior year or checked "Other," explain on
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?
2a
No
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
b
Were the organization’s financial statements audited by an independent accountant?
2b
Yes
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
c
If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight
of the audit, review, or compilation of its financial statements and selection of an independent accountant?
2c
Yes
If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
3a
Yes
b
If "Yes," did the organization undergo the required audit or audits?
If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.
3b
Yes
Form
990
(2021)
Form 990 (2021)
Additional Data
Software ID:
Software Version:
Form 990, Special Condition Description:
Special Condition Description